Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trial
Official title:
Evaluation of the Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD - A Double-Blind, Placebo-Controlled, Dose-Ranging Study
Verified date | August 2020 |
Source | Supernus Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This was a randomized, double-blind, placebo-controlled, multicenter, 5-arm, parallel-group, dose-ranging study to assess the efficacy and safety of SPN-812 (Viloxazine Extended-release Capsule) in children 6-12 years of age with ADHD.
Status | Completed |
Enrollment | 222 |
Est. completion date | July 25, 2016 |
Est. primary completion date | July 25, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 12 Years |
Eligibility | Inclusion Criteria: 1. Healthy male or female subjects, 6-12 years of age, inclusive, with a diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM IV), confirmed with the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). 2. ADHD-RS-IV-Parent Version: Investigator Administered and Scored score of at least 26. 3. CGI-S score of at least 4 4. Weight of at least 20 kg. 5. Free of medication for the treatment of ADHD or any psychosis for at least one week prior to enrollment. Exclusion Criteria: 1. Current or lifetime diagnosis of major depressive disorder, bipolar disorder, personality disorder, Tourette's disorder, or psychosis not otherwise specified. 2. Currently meeting DSM-IV criteria for pervasive developmental disorder, obsessive compulsive disorder, post-traumatic stress disorder, or any other anxiety disorder as primary diagnosis. 3. Significant systemic disease. 4. Evidence of suicidality within the six months before Screening or at Screening. 5. BMI greater than 95th percentile for the appropriate age and gender. 6. Pregnancy or refusal to practice abstinence during the study for female subjects of childbearing potential (FOCP). 7. Substance or alcohol use during the last three months. 8. Positive urine screen for cotinine, alcohol, or drugs of abuse at Screening. |
Country | Name | City | State |
---|---|---|---|
United States | Florida Clinical Research Center, LLC | Maitland | Florida |
Lead Sponsor | Collaborator |
---|---|
Supernus Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Efficacy of SPN-812 on the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) | The Primary Endpoint was the change from baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition (ADHD-RS-IV) Total score at Week 8 (End of Study). The ADHD-RS-IV is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology. The scale consists of 18 items that directly correspond to the 18 Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) symptoms of ADHD. Each item is rated on a 4-point Likert-type scale from 0 (never or rarely) to 3 (very often). A Total score is calculated by adding the responses of all 18 items (range: 0-54; the higher the score, the more severe the ADHD symptoms). Lower change from baseline scores (<0) represent a better outcome. | Baseline to Week 8 (End of Study) | |
Secondary | Effect of SPN-812 on Clinical Global Impression - Improvement (CGI-I) Scale | The first additional secondary endpoint was the Clinical Global Impression-Improvement (CGI-I) Scale score at Week 8 (End of Study). The CGI-I scale is a single item assessment of how much the patient's illness has improved or worsened relative to a baseline state prior to the beginning of treatment. The CGI-I is rated on a 7-point Likert scale from 1 to 7, where 1 = "Very much improved", 2 = "Much improved", 3 = "Minimally improved", 4 = "No change", 5 = "Minimally worse", 6 = "Much worse", and 7 = "Very much worse". Successful therapy is indicated by a lower score (<4) in subsequent testing. | Week 8 (End of Study) | |
Secondary | Effect of SPN-812 on the Clinical Global Impression - Severity (CGI-S) Scale | The second additional secondary endpoint was the change from baseline in the Clinical Global Impression-Severity (CGI-S) Scale score at Week 8 (End of Study). The CGI-S scale is a single item clinician/investigator rating of the clinician's assessment of the severity of the ADHD symptoms in relation to the clinician's total experience with patients with ADHD. The CGI-S was rated on a 7-point Likert scale, where 1 = Normal, not at all ill, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Extremely Ill. Successful therapy is indicated by a lower CGI-S score in subsequent testing. A lower change from baseline score (<0) represents a better outcome. | Baseline to Week 8 (End of Study) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02150668 -
Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD
|
N/A | |
Completed |
NCT00631280 -
Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD
|
N/A | |
Recruiting |
NCT05809388 -
Virtual Reality for Parent Training Intervention
|
N/A | |
Completed |
NCT00776009 -
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
|
Phase 4 | |
Recruiting |
NCT00252278 -
Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents
|
Phase 4 | |
Completed |
NCT04016779 -
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
|
Phase 3 | |
Completed |
NCT00307268 -
Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD
|
N/A | |
Completed |
NCT01107496 -
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
|
Phase 1/Phase 2 | |
Completed |
NCT04786990 -
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
|
Phase 4 | |
Completed |
NCT00475735 -
A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00711724 -
Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD
|
N/A | |
Recruiting |
NCT06215144 -
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
|
Phase 2/Phase 3 | |
Withdrawn |
NCT00323700 -
A Naturalistic Prospective Study of Treatment Effectiveness for Attention-Deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
Not yet recruiting |
NCT04532190 -
Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder
|
N/A | |
Withdrawn |
NCT00931398 -
Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate
|
Phase 4 |